Wall Street analysts expect Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to report sales of $545.28 million for the current quarter, Zacks reports. Four analysts have made estimates for Amneal Pharmaceuticals’ earnings. The lowest sales estimate is $532.73 million and the highest is $556.90 million. Amneal Pharmaceuticals posted sales of $519.29 million in the same quarter last year, which would indicate a positive year over year growth rate of 5%. The firm is expected to issue its next quarterly earnings results on Friday, November 5th.
According to Zacks, analysts expect that Amneal Pharmaceuticals will report full-year sales of $2.14 billion for the current fiscal year, with estimates ranging from $2.12 billion to $2.15 billion. For the next year, analysts expect that the business will report sales of $2.19 billion, with estimates ranging from $2.17 billion to $2.21 billion. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Amneal Pharmaceuticals.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings results on Sunday, August 8th. The company reported $0.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.18 by $0.07. The firm had revenue of $535.10 million for the quarter, compared to analyst estimates of $523.26 million. Amneal Pharmaceuticals had a return on equity of 58.68% and a net margin of 0.45%. The business’s quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.13 EPS.
Shares of NYSE:AMRX traded up $0.01 during trading on Friday, hitting $4.96. 1,651,519 shares of the company were exchanged, compared to its average volume of 1,383,272. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of 82.67, a P/E/G ratio of 0.25 and a beta of 1.22. Amneal Pharmaceuticals has a fifty-two week low of $3.76 and a fifty-two week high of $7.45. The firm has a fifty day moving average price of $5.00 and a two-hundred day moving average price of $5.52. The company has a current ratio of 2.32, a quick ratio of 1.55 and a debt-to-equity ratio of 7.07.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Amneal Pharmaceuticals by 3.5% in the 2nd quarter. Vanguard Group Inc. now owns 11,496,667 shares of the company’s stock valued at $58,863,000 after buying an additional 391,756 shares in the last quarter. BlackRock Inc. grew its holdings in Amneal Pharmaceuticals by 3.5% in the 1st quarter. BlackRock Inc. now owns 7,664,792 shares of the company’s stock valued at $51,583,000 after buying an additional 257,997 shares in the last quarter. Eversept Partners LP grew its holdings in Amneal Pharmaceuticals by 303.6% in the 1st quarter. Eversept Partners LP now owns 4,755,480 shares of the company’s stock valued at $32,004,000 after buying an additional 3,577,327 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Amneal Pharmaceuticals in the 1st quarter valued at $19,732,000. Finally, State Street Corp lifted its position in shares of Amneal Pharmaceuticals by 12.5% during the 2nd quarter. State Street Corp now owns 2,738,815 shares of the company’s stock valued at $14,023,000 after acquiring an additional 303,813 shares during the period. 32.91% of the stock is currently owned by hedge funds and other institutional investors.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals.
Featured Story: Debt-To-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.